United Therapeutics CORP Form 4 insider transactions

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a series of transactions involving the exercise of stock options and sale of common stock on April 1, 2026, under a 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported significant transactions involving common stock and stock options on March 31, 2026.

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, executed a pre-arranged 10b5-1 plan, exercising stock options and selling common stock.

United Therapeutics CFO and Treasurer James Edgemond exercised stock options and subsequently sold common stock shares totaling 7,986 under a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Christopher Causey executed a pre-planned sale of 1,300 common shares following the exercise of stock options.

United Therapeutics' Chairperson and CEO, Martine A. Rothblatt, exercised stock options and subsequently sold shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics' CFO and Treasurer, James Edgemond, exercised stock options and subsequently sold a significant portion of the acquired shares under a Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised stock options and sold resulting shares totaling 9,500 under a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Tommy G Thompson exercised stock options and subsequently sold a portion of his common stock holdings on March 26, 2026.

United Therapeutics' Chairperson and CEO, Martine A. Rothblatt, exercised stock options and sold shares totaling 9,500 under a pre-arranged 10b5-1 trading plan.

United Therapeutics CFO James Edgemond exercised stock options and sold a portion of common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics' Chairperson and CEO, Martine A. Rothblatt, executed pre-planned stock option exercises and subsequent sales of common stock on March 23, 2026.

United Therapeutics Director Judy D. Olian sold 200 shares of common stock for $530 per share under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, executed a pre-arranged sale of 9,500 common shares following an option exercise.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised stock options and sold resulting shares under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, exercised stock options and sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 8,300 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold shares as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, reported the vesting of restricted stock units and related share transactions, including tax withholdings and an Employee Stock Purchase Plan acquisition.

United Therapeutics CFO James Edgemond reported the vesting of restricted stock units and subsequent tax-related share withholdings, alongside an Employee Stock Purchase Plan acquisition.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, reported the vesting and conversion of restricted stock units into common stock, with a portion withheld for taxes.

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, reported the vesting of restricted stock units and subsequent share adjustments for tax purposes.

United Therapeutics Director Jan Malcolm sold 45 shares of common stock for $533.51 per share under a pre-arranged 10b5-1 trading plan.

Judy D. Olian, a director at United Therapeutics Corp, sold 200 shares of common stock for $535.44 per share under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold resulting shares as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's Chairperson & CEO, Martine A. Rothblatt, executed a planned sale of common stock following option exercise.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 8,300 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine A. Rothblatt exercised stock options and sold 9,500 shares of common stock as part of a pre-arranged 10b5-1 trading plan.